Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Increase in Short Interest

Context Therapeutics Inc. (NASDAQ:CNTX) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 40,400 shares, a growth of 260.7% from the March 31st total of 11,200 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily volume of 55,500 shares, the days-to-cover ratio is currently 0.7 days.

Context Therapeutics Price Performance

NASDAQ CNTX traded up $0.03 on Friday, reaching $1.41. 19,984 shares of the stock were exchanged, compared to its average volume of 51,268. Context Therapeutics has a one year low of $0.47 and a one year high of $1.69. The company’s 50-day simple moving average is $1.25 and its two-hundred day simple moving average is $1.13.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.07). As a group, research analysts anticipate that Context Therapeutics will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their price target on shares of Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, March 21st.

Institutional Investors Weigh In On Context Therapeutics

An institutional investor recently bought a new position in Context Therapeutics stock. Opaleye Management Inc. acquired a new stake in shares of Context Therapeutics Inc. (NASDAQ:CNTX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 975,000 shares of the company’s stock, valued at approximately $1,102,000. Opaleye Management Inc. owned approximately 6.11% of Context Therapeutics at the end of the most recent reporting period. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.